Hoffman et al. demonstrated that EGCG was able to block constitutive and IL-1-dependent NF-kB activation as well as production of tumorigenic factors in pancreatic cancer (Hoffmann et al., 2011). This evidence concerns the gene IL1B and familial pancreatic carcinoma.